fig1

Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers

Figure 1. Glucose metabolic reprogramming regulates sensitivity to antitumor therapy. cGAS/STING: Cyclic GMP-AMP synthase/stimulator of interferon gene; ERK/AKT: extracellular regulated protein kinases/protein kinase B; HK2: hexokinase 2; PGK1: phosphoglycerate kinase 1; PKM2: pyruvate kinase M2; HIF-1α: hypoxia-inducible factor-1α; PEKB3: phosphofructokinase-2/fructose-2,6-biphosphatase 3; LDHA: lactate dehydrogenase A; c-Myc: cellular Myc; ALODA: aldolase A.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/